OrsoBio Stock
HealthTechLooking to sell OrsoBio stock or options?
OrsoBio is a clinical-stage biopharmaceutical company focused on creating treatments for organ dysfunction. The firm is dedicated to developing therapies for obesity and related disorders, such as type 2 diabetes, MASH, and severe dyslipidemia. OrsoBio aims to enhance patients' energy metabolism, offering them improved health outcomes.
Investors Include:
Nueva Bio, National Institute of Diabetes and Digestive and Kidney Diseases, Woodline Partners, Longitude Capital, Enavate Sciences, NuevaBio, Ascenta Capital, Eli Lilly and Company, Samsara BioCapital.